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Abstract 
Background: Medicinal plants have contributed significantly to current malaria treatment. 
Alarming signs of emerging resistance to currently available drugs has necessitated the search for 
new plant based antimalarial agents and several plant based, pharmacologically active anti-malarial 
compounds have been isolated. This study was conducted to validate the traditional usage of 
C.simensis for treating malaria in the traditional health care system of Ethiopia. 
Methods: The roots of C.simensis were collected around Gondar town, 738km North West 
Ethiopia. After collection, the plant materials were identified by a taxonomist, dried under shade 
and crushed to powder. The powdered roots were extracted by maceration using 80 % methanol and 
fractionated using n-hexane, chloroform and distilled water. Acute toxicity study of the crude 
extract was carried out in female Swiss albino mice. The in vivo anti-malarial activities of crude, 
aqueous, chloroform and n-hexane fractions  (100, 200,400 and 600 mg/kg) of C.simensis roots 
against a chloroquine (CQ) sensitive strain of P. berghei strain ANKA was evaluated using the 
four-day suppressive and curative test procedures. Parameters such as parasitemia, packed cell 
volume, rectal temperature, body weight and survival time were then determined.  
Results: The 4-day suppressive oral administration test of the 600mg/kg methanolic crude extract 
(P <0.001) and 400mg/kg chloroform fraction (P <0.01) showed significant parasitemia reduction 
compared with the negative control. And their respective percentage suppressions were 53.54 and 
26.45. Additionally, the curative test of chloroform fraction achieved significant parasitemia 
reduction for 600mg/kg (P <0.001) and 400mg/kg (P <0.05) in relation with negative control. The 
activities of all the extracts on P. berghei-infected mice were increased in a dose-dependent 
manner. Its oral LD50 was found to be greater than 2000 mg/kg. 
Conclusion: The result revealed the methanolic crude extract and chloroform fraction of 
C.simensis roots have anti-malarial activities against P. berghei in an animal model and supports 
the use of the plant to combat malaria in Ethiopian folk medicine. Further work is necessary to 
isolate, identify and characterize the active principles from the plant material. 
Keywords: In-vivo, Anti-malarial, C.simensis, crude extract, solvent fractions P. berghei, 4-day 
suppressive, curative and phytochemicals.  
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1. Introduction 
Malaria is a vector borne infectious disease caused by hemo- protozoan of the genus 
Plasmodium, phylum Apicomplexa and family Plasmodidae(1, 2). The disease is transmitted by 
the bite of infected adult female Anopheles mosquitoes (3). It is a critical health problem in the 
world and one of the top three killer infectious diseases (HIV/AIDS, TB and malaria,) 
globally(4).         
1.1. Epidemiology and economic impact of malaria 
Knowing the features of malaria in endemic populations is a key part in quantifying and 
monitoring the impact of current and past control efforts (5). Malaria was endemic in 104 
tropical and subtropical countries, including parts of the Americas, South-East Asia and Africa 
(5-7). and has a major impact on global public health and the economy, with an estimated 3.3 
billion people at risk in 2011(WHO)(2, 8).   
According to WHO-2012, the disease is preventable and treatable, yet annually there were 207 
million estimated cases from which 627,000 deaths of malaria and majority of cases (80%) and 
deaths (90%) accounting in Sub-Saharan Africa-SSA (9-11).  In 2013, WHO estimated that 
malaria caused about 198 million illnesses and 584 000 deaths globally. Africa is the most 
affected continent with 90 % of all malaria deaths mainly in children under 5 years old (8). There 
were 214 million new cases of malaria in 2015 globally (WHO)-Africa accounted - 88%, South -
East Asia-10% and Eastern Mediterranean (2%). From 438,000 malaria deaths worldwide  
under-fives accounting 306, 000(2, 12).Malaria has placed a heavy economic burden on health 
systems especially in Africa, on average it costs 300 million US Dollars for case management 
per year(12). 
Malaria is one of the leading health problems in developing countries including Ethiopia. In 
Ethiopia malaria is unstable and seasonal as the country’s heterogeneous topography and climate 
conditions(13). Malaria affects more than 68% of the population in Ethiopia, a country of 94 
million people in 2013. Across the nine administrative regions, areas that lie below 2000 m 
altitude are malarious.  The high malaria transmission season overlaps with the cultivation 
months; hence it has a deleterious effect on agricultural production (14, 15) Studies showed, 
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history of travel is a risk factor for malaria in Ethiopia. The major driving force for macro-level 
population movements is seasonal agricultural labor (10). 
1.2. Life cycle and pathophysiology of malaria 
1.2.1. Life cycle of malaria 
Infection is initiated when a parasitized Anopheles mosquito injects tens to hundreds of 
sporozoites into the dermis of the host (16).Sporozoite stage traverses multiple host skin cell 
types, taken up by the blood stream and transported to the sinusoids of the liver and each parasite 
establishes itself in a single hepatocyte and infect it (17). In most Plasmodium species, all 
parasites then undergo many rounds of replication for 5-12 days, depending on spp., in a single 
hepatocyte as liver schizonts and ultimately form tens of thousands of infectious  merozoites (17, 
18). 
P. vivax and P. ovale have a dormant stage, named hypnozoite that can remain in the liver for 
several months to years before the development of pre-erythrocytic schizogony resulting in 
relapses of malaria infection. P. malariae can result in long-lasting infections and if untreated 
can persist asymptomatically in the human host for many years, even a lifetime (19).Merozoites 
are released in to the circulation and begin the asexual blood stage where cyclic infection, 
replication and lytic release from red blood cells (RBCs) occur. This rapidly multiplies the 
parasite in to billions and causes all malaria-associated morbidity and mortality (19). 
A small percentage of asexual stages terminally differentiate into sexual erythrocytic stages (3, 
20).After these sexual stages are taken up by a female anopheline mosquito while ingesting a 
blood meal, they mate and infect the mosquito’s mid gut. Further differentiation and expansion 
of parasites generates thousands of progeny sporozoites and that travel to the mosquito’s salivary 
glands (21). 
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Figure 1 Life cycle of the malaria (22). 
1.2.2. Pathophysiology of malaria 
A lot of Plasmodium species infect humans and other animals, including rodents’ birds and 
reptiles (23). Of the five Plasmodium SPP.(P. falciparum, P. vivax, P .ovale and P. malariae) 
that infect humans, P. vivax and P. falciparum cause the majority of cases, and P. falciparum is 
the most virulent and responsible for most of the deaths (24). (P. knowlesi, the fifth occasional 
human parasite is essentially a non-human primate malaria species found in Southeast Asia (11). 
In Ethiopia, P. falciparum and P. vivax are the main species accounting about 60% and 40% of 
malaria cases, respectively (25). More than 400 species of the Anopheles mosquito have been 
described and about  70 of  these species are potential vectors of malaria that affect humans 
(23).The dominant malaria vector in Ethiopia is Anopheles arabiensis; and Anopheles 
pharoensis, Anopheles funestus and Anopheles nili are secondary (25). 
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The pathogenesis of human malaria emanates from various host and parasite factors that 
simultaneously influence the severity and outcome of the disease. Important pathophysiologic 
features include the induction of pro-inflammatory cytokines, the sequestration of P. falciparum-
infected erythrocytes in the microvasculature, and anemia due to suppression of erythropoiesis. 
The destruction of infected and uninfected erythrocytes further compromises oxygen delivery 
and exacerbates disease pathogenesis (26).  
In P. falciparum the blood stage schizonts disappear from the circulation because they adhere to 
host ligands on endothelial cells of the microvasculature of  various  organs throughout the body 
including the brain and  placenta, through parasite proteins expressed on the infected erythrocyte 
surface leading to sever pathogenesis such as cerebral malaria or adverse effects during 
pregnancy( placental complications)(27). Important virulence properties of P. falciparum are 
sequestration and the expression of parasite-derived antigens (comprised of novel parasite-
derived proteins including P. falciparum erythrocyte membrane protein 1 (PfEMP1)) on the 
surface of infected erythrocytes and the adhesion of it to the vascular endothelium or to 
uninfected erythrocytes to form rosettes which results in excessive microvasculature obstruction. 
(The clustering of mature infected erythrocytes to uninfected erythrocytes, known as rosetting 
(26). 
The proteins of the P. falciparum stevor and rifin multi-gene families are involved in infected 
erythrocyte interactions such as rosetting and tissue sequestration. Stevor-induced rosetting 
provides a growth advantage by protecting merozoites from invasion by blocking antibodies(28).  
A feature of infected erythrocyte that enables P. falciparum to sequester is the expression of 
knob structures on the infected erythrocyte’s membrane. The structural component of knobs is 
the knob-associated histidine-rich protein, KAHRP (major), PfEMP2 and PfEMP3. KAHRP 
enables reduced membrane deformability of both infected and uninfected erythrocytes 
compromising their passage via partially obstructed capillaries and venules and shortens RBC 
survival(26). 
Large proportions of these exported proteins encoded by multi-copy gene families involve in 
antigenic variation and immune evasion. These Plasmodium proteins are involved in uptake of 
nutrients, formation of membranous structures, and protein trafficking and mediating adherence 
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of infected erythrocytes to host cell receptors. These proteins operate as ligands that bind to host 
cell receptors on the capillary endothelium resulting in infected erythrocytes tissue sequestration, 
which is believed to prevent infected erythrocytes from being removed by the spleen (28). 
The parasite proliferation within the host’s erythrocyte takes place using hemoglobin as nutrition 
source. Massive degradation of the hemoglobin within the digestive vacuole of the parasite 
generates large amount of toxic soluble heme. To protect itself, the parasite polymerizes the 
heme to an insoluble crystalline pigment known as hemozoin, which is sequestered in the food 
vacuole. Hence, hemozoin synthesis is an indispensable process and the target of action of 
several antimalarials (29) 
1.3. Diagnosis and Management of malaria 
1.3.1. Diagnosis of malaria 
Early and effective malaria diagnosis is the main thrust for control and management of the 
disease. Till now peripheral blood smear remains the gold standard for the diagnosis of 
Plasmodium species and to determine the disease burden(29). In many hospitals and health 
centers diagnosis is carried out by microscopy, whereas the health posts employ rapid diagnostic 
tests (RDT), relatively require no skilled personnel, for P. falciparum and P. vivax diagnosis(25). 
The tests contain antibodies conjugated to latex particles that bind to the circulating antigens(29).  
Some malaria parasites lack the histidine rich protein 2 (HRP2) proteins, the most common 
target antigen used in RDTs for detection of P. falciparum. Hence, the parasites can escape 
detection by rapid diagnostic tests and subsequent treatment with an ACT. This prevents a 
patient from receiving appropriate treatment, enables the parasite to survive, reproduce and 
increase in relative frequency (30). RDTs do not allow quantification and differentiation of 
different Plasmodium species other than P. falciparum and P. vivax (25). 
 Recently molecular detection of Plasmodium with higher sensitivity is gaining paramount 
importance for accurate detection. Polymerase chain reaction (PCR) detects parasite DNA and 
can identify infections below the threshold of detection for microscopy and RDTs in blood. The 
PCR approach identifies the species-specific Plasmodium DNA by amplifying the 18s rRNA 
region of the parasite (highly sensitive but too complex)(29).  Mixed infections are best detected 
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by PCR amplification techniques; they may be underestimated with routine microscopy(18). 
Currently, PCR is mainly used in drug efficacy studies. Neither is used for clinical managements 
(31). 
1.3.2. Management of malaria 
Malaria case management including early diagnosis and prompt effective treatment, remains a 
vital component of malaria control and elimination strategies (18).The main guiding factors 
those need to be focused during treatment are; the type of infecting Plasmodium species, clinical 
status of the patient and drug susceptibility of the infecting parasites as determined by the 
geographic area where the infection was acquired and the previous use of antimalarial medicines 
(32).  
1.3.2.1. Treatment of uncomplicated P. falciparum malaria 
Most of the countries with P. falciparum malaria have been adopted ACTs as a first-line 
treatment. According to WHO recommendation, uncomplicated P. falciparum malaria should be 
treated with an ACT (both children and adults) (18). In areas where there is artemisinin 
resistance and in areas targeted for P. falciparum elimination, a single primaquine dose (0.25 
mg/kg) is given for all patients with confirmed P. falciparum on the first day of their ACT 
treatment. A single dose of primaquine was being utilized for gametocidal treatment of P. 
falciparum cases in 39 low-transmission countries for the reduction of malaria transmission (8, 
18) 
Even though use of primaquine in radical curative regimens needs glucose-6- phosphate 
dehydrogenase (G6PD) testing, a single low dose of primaquine as a P. falciparum 
gametocytocide has proved safe and well tolerated in G6PD deficient patients (2).    
In the previous years, chloroquine was effective in treating almost all cases of malaria. In 2013, 
ACTs had been adopted as national policy for first-line treatment in 79 out of 87 countries where 
P. falciparum is endemic; chloroquine is used in 10 Central American and Caribbean countries 
where it remains efficacious (8, 18).  
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1.3.2.2. Treatment of severe malaria  
Mortality rate from untreated severe malaria (particularly cerebral malaria) is about 100%. But if 
prompt, effective antimalarial treatment and supportive care is employed, the overall rate falls to 
10 - 20%.There are two classes of drugs for parenteral treatment of severe malaria: artemisinin 
derivatives (artemether or artesunate) and cinchona alkaloids (quinidine and quinine). Parenteral 
artesunate is the treatment of choice for all severe malaria as it is simpler and safer to use (18). 
Adults and children with severe malaria (including infants, pregnant women in all trimesters and 
lactating women)must be treated with intravenous or intramuscular artesunate for at least 24 h 
and until they are able to take oral medications. Once a patient has received at least 24 h of 
parenteral therapy and can tolerate oral therapy, complete treatment with 3 days of an ACT. If 
parenteral artesunate is not available, we can use artemether in preference to quinine for treating 
children and adults with severe malaria (18).         
1.3.2.3. Treatment of uncomplicated non-falciparum malaria  
Treatments for unknown blood stage malaria species infection is the same as for uncomplicated 
P. falciparum malaria. In chloroquine effective areas, four of the plasmodium spp. malaria are 
treated with either ACT (except pregnant women in their first trimester) or chloroquine in both 
adult and children (18).  In areas where resistance to chloroquine has been detected, four of the 
plasmodium spp. malaria is treated with an appropriate ACT (8). Pregnant women in their first 
trimester who have chloroquine-resistant P. vivax malaria is treated with quinine (18).           
For the avoidance of relapses in P. vivax or P. ovale chloroquine and ACT must be combined 
with a 14-day course of primaquine  (except pregnant women and infants aged less than 6 
months) by taking a risk of hemolysis in to consideration in patients with glucose-6- phosphate 
dehydrogenase (G6PD) deficient(29).In 2013, 55 out of 56 countries with transmission of P. 
vivax malaria, primaquine are being utilized for the treatment of the hypnozoite stage of P. vivax 
malaria (8).    
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1.3.2.4. Treatment of uncomplicated P. falciparum malaria in special risk groups 
Pregnant women with uncomplicated P. falciparum malaria during the first trimester should be 
treated with 7 days of quinine + clindamycin. Infants weighing < 5 kg with uncomplicated P. 
falciparum malaria should be treated with ACT at the same mg/kg body weight target dose as for 
children weighing 5 kg. In people who have HIV/AIDS and with uncomplicated P. falciparum 
malaria, we must avoid artesunate + SP if they are being treated with co-trimoxazole, and 
artesunate + amodiaquine if they are being treated with efavirenz or zidovudine (18).      
1.3.2.5. The role of Traditional medicine in malaria treatment 
People have been used medicinal plants from time immemorial (11). There are 1200 plant 
species from 160 families used to treat malaria globally (33, 34).They are safe, economical, less 
toxic and a reliable key natural source of drugs all over the world.  Phytochemicals are naturally 
occurring in the medicinal plants, leaves, roots and vegetables that have defense mechanism and 
protect us from various diseases. They are primary (chlorophyll, proteins and common sugars) 
and secondary (terpenoids, alkaloids and phenolic etc.) compounds (35). Seasonal variations can 
affect the chemical constituent of the plants and thus their biological activity, maximum at the 
time of flowering and then declines at the beginning of the fruiting stage (36).  
Populations in most endemic countries are highly dependent on the use of plant-based 
complementary medicine for therapy, as most of them lack the access to modern healthcare 
facilities. According to the World Health Organization (WHO) estimates, arround 80% of the 
populations in developing countries including Ethiopia use traditional medicines (37, 38). Drugs 
derived from natural sources, especially plants, represent majority of the pharmaceutical market, 
particularly for malaria therapy. Their advantage for the development of new drugs arises from 
the synergistic interactions of their components and their innate affinity for biological receptors. 
Justification of these principles could provide pharmacological basis for further development of 
plant-based traditional medicine as a reliable therapeutic tool(39).       
In Ethiopia, the use of traditional medicinal plants is widely practiced. Traditional therapies are 
the most important and sometimes the only source of remedies for most of the Ethiopian 
population and 95% of which are plant origin(40).        
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1.3.2.6. Prevention, Chemoprophylaxis and Control of malaria 
Malaria control becomes an increasingly important international focus(29).  Malaria cases can be 
prevented by vector control (stopping mosquitoes from biting human beings), by 
chemoprevention (providing drugs that suppress infections) or, potentially, by vaccination (30).         
 Studies in malaria endemic areas of SSA- countries, including Ethiopia, showed that the 
combination of widespread distribution of long-lasting insecticidal nets to all households (reduce 
malaria incidence rates by 50%, and mortality rates by 55% in children aged under 5 years in 
SSA) indoor residual spraying (IRS), and nationwide distribution of artemisinin-based 
combination therapy (ACT) in the public sector were major control tools associated with 
substantial declines of malaria (29, 30).        
Chemoprevention is vital in pregnant women and young children(29).In SSA, intermittent 
preventive treatment of malaria in pregnancy by sulfadoxine-pyrimethamine (SP) has been 
shown to reduce low birth weight, perinatal mortality and maternal anemia. 
 Intermittent preventive treatment in infants with SP provides protection against clinical malaria 
and anemia; but, as of 2015, no countries have been implemented this policy. 
Seasonal malaria chemoprevention with amodiaquine, AQ + SP for children 3–59 months old 
decreases the incidence of clinical attacks and severe malaria by about 80% and could avert 
millions of cases and thousands of (30).         
1.4. Vector insecticide and antimalarial drug resistance  
Resistance of malaria vectors to the four insecticide classes currently being used in insecticide-
treated nets (ITNs) and IRS threatens malaria prevention efforts. from the 73 malaria endemic 
countries that provided monitoring data to WHO for 2010 onwards, 60 of them reported 
resistance to at least one insecticide in one malaria vector from one collection site, and 50 
reported resistance to ≥ 2 insecticide classes. Resistance to pyrethroids - the only class currently 
used in ITNs-is the most commonly reported (30) .  
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Resistance to all antimalarial drug classes seems to originate from a specific area of the world 
South East Asia (SEA)-mainly human migration especially young who travel extensively in 
forested areas and forest-dwelling mosquitoes render conventional vector control methods less 
effective, resulting in a greater dependence on drugs for malaria control(2).   
Recent genetic studies analyzing microsatellite markers surrounding the P. falciparum 
chloroquine resistance transporter gene (pfcrt) (2), 424-peptide transmembrane protein involved 
in nutrient transport and osmotic balance across the parasite digestive vacuole 
membrane(41).,have confirmed that chloroquine resistance did spread from Asia to Africa. Using 
the same technique the main form of Sulfadoxine pyrimethamine resistance (triple 51, 59 and 
108 dihydrofolate reductase (dhfr) gene mutations) was shown and also spread from SEA to 
Africa (2).                      
The resistance of P. falciparum to artemisinin has been detected in five countries of the Greater 
Mekong sub region, first detected in 2008 (30). The use of oral artemisinin based monotherapy 
medicines threatens the long-term usefulness of ACTs, because it fosters the spread of resistance 
to artemisinin. WHO recommends that oral artemisinin based monotherapies is withdrawn from 
the market and marketing of the products should be stopped (8).               
Previously, many countries have been conducting therapeutic efficacy studies for antimalarial 
medicines. Such studies remain the gold standard for guiding antimalarial treatment policies. 
But, recently, a molecular marker of artemisinin resistance was identified for specific point 
mutations in the Kelch13 (chromosome 13, K13) i.e., propeller domain of P.falciparum protein 
found to be associated with delayed parasite clearance (> 5 h). This may open new possibilities 
for tracking resistance to artemisinin (2, 8).  
1.5. Development of malaria vaccine  
Malaria vaccine research began in the 1930s by focusing on inactivated or killed parasites that 
failed to generate a protective immune response but still antimalarial immunity is poorly 
understood(42).  Malaria is caused by more complex parasites in terms of their biology than the 
viruses and bacteria for which we have vaccines. They pass through multiple stages of 
development in the human host expressing hundreds of unique antigens. This complexity makes 
    
11 
 
it more difficult to develop a vaccine for parasites than for viruses and bacteria, since an immune 
response targeting one stage may not offer protection against diverse later stage antigens. In 
addition, depending on the life cycle stage and whether the parasite is extra-or intra-cellular, 
antibody and/or cellular immune responses provide protection(43). To date, malaria vaccination 
strategies have mainly focused on sporozoites and liver stages or blood stage of infection 
targeting stage specific parasite antigens(16). But, success has been limited with these stage-
specific approaches, raising the question to give greater emphasis on multi-stage vaccination 
approaches(16).   
In July 2015, the most advanced malaria vaccine candidate and the first to undergo large-scale 
phase 3 evaluations in Africa, RTS, S/AS01 made by GlaxoSmithKline received a positive 
opinion from European regulators for the first time(44) .This targets the pre-erythrocytic stage of 
P.falciparum inducing humoral and cellular immune responses to the circumsporozoite protein 
(CSP) present on the surface of sporozoites and liver stage schizonts. The development of this 
vaccine is initiated in the late 1980s, and invested about $610 million to date(44, 45).      
RTS, S reduced clinical incidence by 39% and severe malaria by 31.5% among children aged 5–
17 months who completed four doses. WHO recommended that RTS, S be implemented on a 
pilot scale in parts of 3-5 SSA countries in 3–5 years time. The first phase of vaccination is 
expected to commence in 2018. RTS, S is being considered as a complementary malaria control 
tool in Africa that could potentially be added to, rather than replace, the core package of proven 
malaria preventive, diagnostic and treatment interventions (30).      
1.6. Investigational antimalarial agents  
The lethal impact of pfent1 knockout for parasites which are grown in purine concentrations 
found in human blood suggests that it might be a target for the development of novel antimalarial 
drugs, but, no inhibitors of pfent1 have been identified to date (46). 
The new drugs in development are those with known chemical structures and/or mechanism of 
action with enhanced properties- tafenoquine (an 8-aminoquinoline), artefenomel (OZ439)(a 
synthetic peroxide), and P218 (an antifol); and those with new chemical classes such as KAE609 
(a spiroindolone) and KAF156 (an imidazolopiperazine). The threat of potentially untreatable 
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falciparum malaria is real, and will require radical action if malaria is to be eliminated before the 
available drugs become ineffective(2).                      
1.7. Description of the Genus Clematis (Ranunculaceae) 
Members of the genus Clematis are mostly perennial woody vines, few perennial sub-shrubs, 
shrubs or herbs distributed worldwide, predominantly in tropical and subtropical regions. Within 
the subfamily Ranunculoideae of Ranunculaceae, it belongs to the tribe Anemoneae, sub-tribe 
Clematidinae. Family Ranunculaceae comprises 59 genera and about 1900 species. Genus 
Clematis has about 355 spp. in the world (2005)(47, 48).  
 There are reports on the chemotaxonomy of genes Clematis, using flavonoids, triterpenoid 
saponins, ribose, etc profiles as chemical markers for the taxonomy of the Ranunculaceae. Many 
species of Clematis from China are of medicinal significance. Various Clematis species have 
been shown experimentally to exhibit significant anti inflammatory (47, 49) and analgesic, 
antifungal, antitumor, cytotoxic and cyclooxygenase-2 inhibitory activities, which have been 
attributed to the saponins found in the genus (47).Chemical and pharmacological studies have 
shown that triterpenoid saponins are the main components in the genus clematis having a wide 
spectrum of  biological effects (50) 
The volatile constituents of the three Clematis species viz. C. hirsute, C. Simensis and C. 
wightiana showed a pronounced anti-inflammatory activities and volatiles of C. hirsute and C. 
simensis showed similar activities against gram-positive, gram-negative bacteria and fungi 
(51).The ethanol extracts of three Clematis species, C. Pickeringii (with the highest inhibitory 
activities), C.glycinoides and C. microphylla, inhibited the activities of cyclooxygenase-1 (COX-
1), cyclooxygenase-2 (COX-2) and 5-lipoxygense (5-LOX) (52). 
70% EtOH crude extract of young shoots of C. Vitalba was shown broad activity against 
pathogenic yeast and yeast-like microorganisms. After fractionating with petroleum ether, ethyl 
acetate and methanol, antimycotic activity has been observed only in methanol fractions and 
triterpenoid saponins were also isolated in this plant (53).The roots and rhizomes of genus Clematis are 
commonly used as an analgesic, abirritative, anti-inflammatory, antibacterial, antiphlogistic, 
anticancer and diuretic agent (54).  
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A study showed the hepatoprotective effect of C. chinensis extract on CCL4-induced 
hepatotoxicity in rats and the results of aminetransferase, aspartate aminetransferase and alanine 
aminetransferase have shown a significant hepatoprotective effect after treatment with C. 
Chinensis (52). Medicinally effective chemical compounds are apparently absent in young 
sprouts therefore young sprouts of various Clematis spp. are eaten cooked as vegetable (55). 
The Izoceno-Guarani of Bolivia burned the aerial parts of C. denticulata Vell. cabelo del angelo. 
over fire and inhaled the smoke to treat malaria (56).Various African herbs (e.g. C. brachiata, C. 
hirsuta and C. oweniae) were used to induce sneezing to clear head colds or headaches. Patients 
suffering from malaria and colds boiled C.oweniae in hot water and taken it as a tea (57). 
Twenty six species of the genus Clematis have been traditionally used in various systems of 
medicine for the treatment of ailments such as nervous disorders, syphilis,  malaria, dysentery, 
rheumatism, asthma, and as analgesic, anti-inflammatory, diuretic, antitumor, antibacterial and 
anticancer (58) 
According to “Chinese Materia Medica” C. terniflora DC. Var. mandshurica (Rupr) Ohwi, C. 
mandshurica Rupr, C. meyeniana Walp, C. uncinata Champ. Ex Benth, and C. uncinata Champ. 
Ex Benth var. biternata W. T. Wang are traditionally used for the treatment of malaria (52). 
Methanolic extract of C.campestris A.St.-Hil. flower, showed good in vitro antiplasmodial 
activity against P. falciparum (59) 
1.8. Experimental plant, C. simensis Fresen. (Ranunculaceae) 
C. simensis is one of the plants that belong to the family Ranunculaceae, which has synonyms – 
C.orientalis,L, L, and C.altissima, Hutc (60, 61)., “Azoareg” in Amharic(62). It is a tall climbing 
shrubby plant, up to ≥ 20 m. The plant grows in an altitude range of 1000-3360m (60, 61).  
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Figure 2- A photographs of C. simensis. 
Ethno pharmacologically -crushed shoots of maceration used for cough treatment (63), crushed 
fresh leaves for tonsillitis, cellulites and leech infection  treatment(for cattle) (64), leaves for 
wound treatment (65). Stem, tooth brush  as antimicrobial (for Streptococcus pyogenes 
(66),leaves chewed and juice swallowed as cure for headache and colds(67, 68), squeezed leaves 
for hemorrhoids/tumor (69), grinding and giving a finger tip of this nasally for malaria treatment 
(68, 70), root/twig-homogenization orally for malaria , cough and liver disease(71).  Root 
decoction drunk for treatment of malaria and as purgative (68). According to the people of 
Burundi, smoke from burning leaves is reported to have analgesic properties (56). 
In addition, in vitro, antibacterial activities of C. simensis leaf extract on Enset Bacterial Wilt 
(Xanthomonas campestris PV Musacearum) in combination with other plants have showed 
moderate inhibitory activities against bacterial isolate in comparison with standard antibiotic-
Penicillin (72). Its leaf extract also experimentally showed in vivo anti inflammatory and anti-
nociceptive activities (49).  
Apart from the above antimalarial claims of the literature no experimental studies have been 
reported on in vivo antiplasmodial effects of extracts of C. simensis Fresen.(Ranunculaceae)  
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1.9. Significance of the study 
Even though malaria is among the preventable and treatable infectious diseases, it is still one of 
the major causes of mortality and morbidity in tropical and subtropical countries  and remains a 
major global health concern with 207 million estimated cases and 627,000 deaths of malaria 
(WHO-2012) (9, 25). Antimalarial drugs currently remain the most effective tool for malaria 
treatment together with vector control strategies and for malaria prophylaxis. Unfortunately, the 
rapid spread of drug-resistant P. falciparum parasites is compromising the efficacy of available 
antimalarial drugs (73).  
Containing resistance is becoming increasingly difficult as P. falciparum develops resistance to 
all antimalarial drug classes. Moreover, increasing numbers of international travelers and 
improved transportation facilitate the spread of resistant parasites (2). Alarming signs of 
emerging resistance to artemisinin derivatives threaten the now widely-used artemisinin core 
combination therapies (ACTs) (39), and the discoveries of new antimalarial agents are urgently 
needed, with broad therapeutic potential and novel modes of action, to widen the scope of 
treatment and to overcome emerging drug resistance in malaria parasites. Drugs that target 
different, preferably multiple, parasite life cycle stages are a high priority(73). 
Quinine (from Cinchona spp.), Atovaquone (from Tabebuia impetiginosa) and recently 
introduced artemisinin (from Artemisia annua) and its derivatives as antimalarials demonstrate 
that plant species are an important source to search for new antimalarial agents (39). In addition, 
many plant species remain to be used in traditional medicines for the treatment of malaria and 
many people depend on such remedies as they cannot afford and even do not have an access to 
effective antimalarial drugs.  
One of the approaches in the search for new antimalarial drugs is the use of more predictive 
traditional herbal remedies which have been served as a source of the majority of conventional 
antimalarial drugs. The interest in this plant is justified by its traditional claims and potential 
medicinal value against malaria and reported pharmacological activities of the leaf extracts for 
anti-inflammatory activity might have antimalarial activities (39, 68, 70, 71). The present study, 
therefore, focuses on investigation of antimalarial activities of crude extract and solvent fractions 
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of C.simensis root in mice infected with P.berghei, hoping that this will provide a base line data 
for further investigations on antimalarial effect of the plant. 
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2. Objectives of the Study 
 2.1. General objective 
 To investigate antimalarial activities of crude extract and solvent fractions of C. simensis 
roots extract in P. berghei infected mice. 
2.2. Specific objectives 
o  To undertake preliminary phytochemical screening of the crude extract of C. 
simensis roots. 
o To determine the oral acute toxicity of C. simensis roots extract. 
o To evaluate the antimalarial activities of the crude extract of C. simensis roots 
using 4 days suppressive test.  
o To evaluate the antimalarial activities of the hexane, chloroform and aqueous 
fractions of C. simensis roots using 4 days suppressive test.  
o To evaluate the antimalarial activities of the most active solvent fraction of C. 
simensis roots using curative tests.  
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3.  Materials and Methods 
3.1. Materials 
Chemicals, drugs and reagents  that were used - Absolute Methanol(Loba Chemie,India ), 
Giemsa stain, Chloroquine Phosphate(APF, Ethiopia), benzene(Blulux laboratories (P) LTD, 
India), Wagner’s reagent, Mayer’s reagent, concentrated H2SO4, Glacial Acetic Acid, sodium 
citrate, Ethanolic Ferric Chloride(Fisher, scientific CO, USA), dilute Ammonia, Acetic 
Anhydride, aqueous hydrochloric acid, copper acetate solution, Chloroform-99.8%(Atico, India). 
3.2. Plant material collection and identification 
The fresh roots of Clematis simensis Fresen were collected around Gondar town, 738km North 
West Ethiopia, in December, 2016 and the plant specimen was identified and authenticated by 
Mr. Abiyu Enyew, Department of Biology, college of Natural and Computational Sciences, 
University of Gondar and the Isotype of the specimen was deposited at their herbarium with a 
Voucher number of MA001 for future reference. 
3.3. Experimental animals and parasite 
Female Swiss albino mice of (age 8-9 weeks and weight of 23-28 g) breed and maintained at the 
University of Gondar, Department of Pharmacology and from the Ethiopian Health and Nutrition 
Research Institute (EHNRI) Addis Ababa, Ethiopia, were used. They were maintained under 
standard condition (temperature of 22 ± 3°C, relative humidity of 50-60% and 12 h light/12 h 
dark cycle), with pellets and water ad libitum in the animal house of University of Gondar, 
School of Pharmacy, Department of Pharmacology . Animals were acclimatized for one week to 
the experimental environment. The care and handling were according to the National Research 
Council Guide for the Care and Use of Laboratory Animals (74-76). 
Chloroquine sensitive strains of P.berghei (ANKA) obtained from EHNRI was used. The 
parasites  were maintained by serial passage of blood from infected mice to non-infected ones on 
weekly basis(77).             
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3.4. Extraction procedure for crude extract 
The collected plant roots were cleaned with tap water and air dried at room temperature under 
shade after slicing it into small pieces to facilitate homogenous drying. A total of 1.9Kg of dried 
roots was extracted by maceration (100g of dried roots in 526ml of 80% methanol) for 72 hrs. 
The extraction process was facilitated by using an orbital shaker at 120 rpm. The mixture was 
first filtered using sieve and then withWhatman filter paper (No.3, 15cm size with retention 
down to 0.1μm in liquids). The residue was re-macerated for another 72 hrs twice and filtered. 
The combined filtrates were dried by rotary evaporator (model-RE200, UK) under reduced 
pressure at a temperature of 40°C (to remove methanol). The remaining aqueous part was further 
dried using a lyophilizer (Ningbo Scientz Biotechnology, China). After drying, a total yield of 
dry extract was determined and kept at −20°C until use. Portion of the crude yield (10g) was 
used for confirmation of the antimalarial activities and the remaining(151g) was used for 
fractionation(78). 
3.5. Fractionation 
The successive solvent-solvent extraction procedure was followed for the fractionation of the 
plant sample. The crude 80% methanolic extract of C.simensis 151g was suspended in 450 ml of 
distilled water in separatory funnels and this was further diluted with 450 ml of n-hexane. After 
gently shaking for 5minutes, the extract was allowed to settle for 25 minutes to be separated into 
two distinct layers according to their density. The upper n-hexane layer was collected and the 
same procedure was repeated three times until colorless n-hexane layer was obtained. After the 
collection of n-hexane fraction of the extract, it was fractionated with 450ml chloroform thrice 
the same way like that of  n-hexane and the bottom chloroform layer was collected leaving the 
aqueous fraction at the top. The n-hexane and chloroform fractions were dried in an oven of 
40oC, and the aqueous fraction was further dried using a lyophilizer.(Ningbo Scientz 
Biotechnology, China). Furthermore, the percentage yield for n-hexane, chloroform and aqueous 
fractions of the plant was determined. These dried fractions were then transferred into separate 
vials and stored at −20°C until use (78-80).  
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3.6. Phytochemical screening  
The secondary metabolites in the plant sample are the main concern of a research work.  A 
preliminary phytochemical study was  performed on crude extract of the roots by coloring and 
precipitation assays using standard procedures to relate the antimalarial activity of the plant with 
the presence or absence of these constituents (36).       
3.7. Acute toxicity testing 
After being fasted for 3hrs, food but not water, five female Swiss albino mice weighing 25-27g 
were taken. The first mouse was given 2 g/kg crude extract (i.e.50mg for 25g mouse); the test 
crude extract solution was administered safely in a single dose orally by gavage. After the 
substance was administered, food was withheld for further 2 hours. The mouse was observed for 
24hrs and it was survived so that we dosed two additional mice and both animals survived and 
the whole mice were observed for any signs of toxicity daily for 14 days to assess safety of the 
extract without dosing of further animals. Animals were observed for gross changes such as loss 
of appetite, hair erection, lacrimation, tremors, convulsions, salivation, diarrhea, weight change 
and other signs of overt toxicity (76).  
3.8. Parasite inoculation 
Female albino mice from the Ethiopian Health and Nutrition Research Institute (EHNRI) Addis 
Ababa, Ethiopia and Gondar University, Gondar, Ethiopia, previously infected with Plasmodium 
berghei (ANKA) and having parasitemia level of 20 and 25% were used as a donor; parasites are 
maintained by serial blood passage from mouse to mouse. Donor mice then sacrificed by head 
blow and blood was collected by severing the jugular vein into a tube containing 0.4% tri-sodium 
citrate. This was diluted with physiological saline (0.9%) based on parasitemia level of the donor 
mice in such a way that 1 ml blood contains 5 × 107 infected erythrocytes .Then each mouse 
were inoculated intraperitoneally with 0.2ml of blood suspension containing about 1×107 P. 
berghei parasitized erythrocytes (77, 78, 81). 
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3.9. Dosing and grouping of animals   
Animals were randomly assigned to five Groups of each consisting of five mice. The Groups I, II 
and III were orally administered with crude extract and solvent fractions of 100,200 and 
400mg/kg of body weight respectively.  Group IV (negative control) was treated with the 
distilled water (chloroform and hexane fractions with 7% Tween-80 suspension) 10ml/kg (77) 
and Group V was administered orally with standard drug (chloroquine 25mg/kg body 
weight)(76).         
3.10. The 4-days suppressive test 
Evaluation of suppressive effect (schizontocidal activity) of the crude extract and solvent 
fractions on early infection against chloroquine sensitive P. berghei infected mice was done. And 
the mice were randomly grouped into five Groups of five mice and inoculated with parasite as 
described above (5.9.). Groups I, II, III were orally administered with the crude extract and 
solvent fractions at doses of 100,200 and 400mg/kg body weight, Group IV was administered 
orally with distilled water, while Group V was administered orally with chloroquine 25 mg/kg 
body weight for four consecutive days(D0-D3) and all treatments were started 3 h post-infection, 
then % inhibition ,parasitemia, weight change and survival time were determined (82).         
3.11. Rane’s test -Curative test 
The curative test was undertaken with chloroform solvent fraction which showed the highest 
parasitemia suppression in the 4-day suppressive test. The mice were injected intraperitoneally 
with standard inoculum of 1x 107 P. berghei infected erythrocytes on the first day (day 0). 
Seventy-two hours later, the mice were divided into five groups of five mice per group as 
described in section 5.9 and treated accordingly. The treatments were continued once daily for 5 
days starting from day 3 through day 7. On days 6, 7 and 8, Giemsa stained thin blood films were 
prepared from the tail of each mouse, then parasitemia level  and  survival time of the  fraction 
were determined with respect to the control groups (78).  
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3.12. Determination of body weight and temperature changes 
For the 4-day suppressive test, body weight of each mouse was measured before infection (day 
0) and on (day-4) using a sensitive digital weighing balance (Item.no.E11140,Switzerland) (82) 
for curative treatment before infection(day0) and (day5). Likewise, rectal temperature was also 
measured with a digital thermometer before infection and after treatment for both test types (82). 
3.13. Peripheral smear test for parasitemia 
After four days of treatment, on the 5th day thin blood smears were made from the tail of each 
mouse (83). The blood films were fixed with methanol, stained with 10 % Giemsa at pH 7.2 for 
10 min, then the stained slides were washed gently using distilled water and air dried at room 
temperature and parasitemia were determined under Olympus microscope (CX21FS1, China) 
with an oil immersion nose piece of 100× magnification by counting 5-fields of approximately 
200 erythrocytes per field. The difference between the mean value of the control group (negative 
control taken as 100%) and those of the experimental groups were calculated and expressed as 
percent parasitemia reduction or activity (77, 81). 
Activity = 100 − (Mean parasitemia treated Mean parasitemia of control)⁄ ∗ 100  
% Parasitemia = (No. of parasitized RBC Total No. of RBC counted) ∗ 100⁄   
3.14 .Packed cell volume measurement (PCV) 
PCV is a measure of the proportion of RBCs to plasma and measured before inoculating the 
parasite and after treatment with the extract .PCV measurement was done to predict the 
effectiveness of the test extract and fractions in preventing hemolysis due to malaria parasites. 
Blood was collected by heparinized capillary tubes from the tails of each mouse. The capillary 
tubes were filled with each mouse’s blood up to 75% of their volume and sealed at the heparin 
end with sealing clay. The tubes were then placed in a hematocrit centrifuge (Hettich 
Hematokrit-210, Germany) with the sealed end outwards and centrifuged for 5 min at 10,000 
rpm. The tubes were then taken out of the centrifuge and PCV was determined using a standard 
Micro-Hematocrit Reader (Hawksley and Sons, England) (84).  
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The relation is as follows; 
PCV = (Volume of erythrocytes in a given volume of blood Total blood volume⁄ ) 
3.15. Determination of mean survival time (MST) 
Mortality was monitored daily and the number of days from the time of inoculation of the 
parasite up to death was recorded for each mouse in the treatment and control groups throughout 
the follow up period. MST for each group was calculated as follows (85).        
MST = (sum of survival days of all mice in a group Total number of mice in that group⁄ ) 
3.16. Statistical analysis 
Results of the study were presented as mean ± SEM. Data was analyzed using SPSS version 20. 
Statistical significance was determined by One-way ANOVA coupled to Tukey’s HSD technique 
to compare result between doses and among treatment and control groups. For all the data 
obtained, the result was considered significant at 95% confidence level and P-value < 0.05. 
3.17. Ethical clearance   
Animal handling were according to the guide lines for Care and Use of Laboratory Animals(74, 
76). Furthermore, procedures were approved by the Institutional Review Board of the University 
of Gondar, Department of Pharmacology 
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4. Results 
4.1. Yield 
Deep yellow semisolid 80% methanolic crude extract of C. simensis roots  was found with the 
percentage yields for crude extract, n-hexane, chloroform and aqueous fractions of the plant 
were; 8.74%, 0.23%, 1.4% and 98.36% respectively. 
4.2. Acute toxicity study 
The acute toxicity study indicated that the tested three mice were survived and then no any signs 
of toxicity for 14 days up to 2g/kg. As a result gross physical and behavioural observation of the 
experimental mice revealed no visible signs of acute toxicity like lacrimation, hair erection, and 
reduction in their motor and feeding activities. Furthermore, they were physically active. Thus 
oral LD50 was found to be greater than the limit dose, 2g/kg body weight. 
4.3. Phytochemical screening 
The summary of the phytochemical constituents of 80%methanolic crude extract of C. simensis 
roots revealed that it showed positive reactions to alkaloids, phenolics, flavonoids and terpenoids 
 
 
 
 
 
 
 
 
    
25 
 
Table 1.Results of phytochemical screening of 80%methanolic crude extract of C. simensis roots 
Phytochemicals Crude extract    Test type Appearance when positive 
Alkaloids + Wagner’s and Mayer’s tests Reddish brown and White creamy 
ppt. 
Tannins _ Braymer’s test Blue/Greenish color 
Saponins _ Foam test Foam 
Flavonoids + Alkaline reagent test Colour less 
Terpenoids + H2SO4(3ml)+Chloroform(2ml) Reddish brown 
Steroids - H2SO4(10ml)+Chloroform(10ml) Brown(bottom),color less (upper) 
Phenols + FeCl3 Bluish black 
Glycosides - Keller-Killani test Brown ring on interface 
Anthraquinones - Chloroform + NaOH Red color 
 
Note - (+) indicates presence, (-) indicates absence, PPT-Precipitate 
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Table 2.Body weight, temperature and PCV measurements in 4 days suppressive test of 80% 
methanolic crude extract of C.simensis roots 
Treatment 
groups(mg/kg) 
 
Wt. before         
 
Wt. after            
 
Temp.before       
 
Temp.after          
 
PCV-before 
 
PCV-after 
Pos.control       23.6±0.3             25±0.75                36.6±0.1          36.4 ±0.2            64.8±3.4                63.8±3.6 
Neg.control       25±0.30               23±0.87               36.5±0.3           34.9±0.1             63.4±2.8                58.4±2.9 
100   25.9±0.9             24.7±0.56            36±0.2              35.3±0.2             60.8±3.2                56.8±2.9 
200   24.9±0.8             23.5±1.2              36.3±0.2           35.4±0.2             60.6±2.7               56.8±2.6 
400   26.8 ±0.8            25.4±0.6             36.7±0.2           36.1±0.1              61.0 ±3.4              57.6 ±3.3 
600   26.4±0.5             25.7±0.4             36.9±0.2           36.2±0.2              58 ±5.5                 55.4±5.1 
 
Table 3.Body weight, temperature, parasitemia, survival time and PCV measurements in 4 days 
suppressive test of 80%methanolic crude extract of C.simensis roots 
Treatment 
groups(mg/kg) 
Wt.diff.(g) Temp.diff.(⁰C %Parasitemia           % supp Survival(days) %PCV.diff 
Pos.control         1.65±0.68 a1 -0.18±0.25
a
3 0.00±0.00
∞
3  30±0.00
∞
3 -1.0±0.45
a
2 
Neg.control        -1.93±0.74 -1.56±0.32 56.82±2.2 0 6.0±0.45 -5±0.1.14 
100 -1.25±0.79 -0.68±0.2 57.6±5.21  6.0±0.32 -4±0.78 
200 -1.4±0.55 -0.88±0.15 50.2±5.38 11.65 6.6±0.40 -3.8±0.74 
400 -1.37±1.37 -0.64±0.09a1 44.6±3.4 21.5 9.0 ±0.55
 a
1
b
1 -3.4 ±0.51 
600 -0.64±0.11 -0.9±0.16a1 26.4±2.15
a
3
b
3
c
3
d
1 53.54 10.2 ±1.07
a
3
b
3
c
2 -2.6±0.6 
 
Results are expressed as mean ±SEM, n=5, a = compared to Neg.control (dis.H2O) 
b=comp.to100mg/kg, c=comp.to 200mg/kg, d=comp.to400mg/kg, e=comp.to.600mg/kg,1= p < 
0.05, 2 = p < 0.01, 3= p < 0.001, ∞ = all treatments 
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Table 4.Body weight, temperature and PCV measurements in 4 days suppressive test of aqueous 
fraction of C.simensis roots 
Treatment 
groups(mg/kg)    
 
Wt.before         
 
Wt. after          
 
Temp.before      
 
Temp.after              
 
PCV.before       
 
PCV.after 
Pos.control            27.6±0.2           27.9±0.2          36.9±0.3             36.8±0.3              56.8±3.2          57.4±3.2 
Neg.control           27.8±0.2           25.5±0.5           37.3±0.2            34.6±0.3               61.2±1.7         54.2±1.9 
100 23.8±0.5           21.9±0.6           36.9±0.1            34.4±0.4              59.2±3.8 52.6±5.3 
200 26.4±0.4           25.1±0.8           36.9±0.1            34.9±0.4              60.4±4.3 54±5.5 
400 27.3±0.1           26.1±0.5            37±0.10              35±0.20               59.2±6.4          54.2±8.1 
 
Table 5.Body weight, temperature, parasitemia, survival time and PCV measurements in 4 days 
suppressive test of aqueous fraction of C.simensis roots 
Treatment 
group(mg/kg 
Wt.diff.(g) Temp.diff.(⁰C)         %Parasitem %Suppn.    Survival/day %PCV.diff 
Pos.control       0.3±0.095a1         -0.10±0.18a2b2c1d1      0.00±0.00∞3  30±0.00∞3    0.6±0.4a1 
Neg.control         -2.32±0.55       -2.7±0.38                      68.4±2.71                 0 5.4±0.24     -7.0±0.45 
100 -1.85±0.95        -2.56±0.51                                   62.2±4.81           9.1                     5.8±0.58      -6.6±1.8 
200 -1.35±0.63       -2.00±0.48                53.5±4.17            21.8                  7.6±0.51        -3.6±2.3 
400 -1.27±0.4          -1.98±0.11               53.2±5.15             22.2                  8.8 ±0.86a2
b
2    -5 ±2.51 
Results are expressed as mean ±SEM, n=5, a = compared to Neg.control (dis.H2O) 
b=comp.to100mg/kg, c=comp.to 200mg/kg, d=comp.to400mg/kg, 1= p < 0.05, 2 = p < 0.01, 3= 
p < 0.001, ∞ = all treatments 
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Table 6.Body weight, temperature and PCV measurements in 4 days suppressive test of hexane 
fraction of C.simensis roots 
Treatment 
groups (mg/kg)    
Wt.before      Wt.after         Temp.before             Temp.after        PCV-before       PCV-after 
Pos.control            25.1±0.7         25.5±0.7                36.5±0.3            36.9±0.4          53.4±2.7            52.6±2.4 
Neg.control           26.8±0.4         24.7±0.2               36.5±0.4                33.9±0.1          52±1.0               46.8±1.9 
200mg/kg              25.1±0.5        23.5±0.6                37.5±0.2           35±0.2             44.2±3.4             41±3.5 
400mg/kg             26.1±0.4          24.8±0.6               36.9±0.2           34.9±0.1          47.4±2.0             44.6±2.3 
 
Table 7.Body weight, temperature, parasitemia, survival time and PCV measurements in 4 days 
suppressive test of hexane fraction of C.simensis roots 
Treatment 
groups(mg/kg) 
Wt.diff.(g Temp.diff.(⁰C)    %Parasitemia    %Supprn.  Survival(days)      %PCV.diff 
Pos.control     0.4±0.09a3b3c2      0.4±0.2∞3            0.00±0.00∞3                               30±0.00∞3         -0.8±0.37a2 
Neg.control        -2.14±0.4         -2.5±0.4                44±6.4                   0                    6.6±0.24              -5.2±1.1 
200           -1.6±0.3            -2.5±0.2               42.7±2.9               3 7.4±0.24                        -3.2±0.4 
400 -1.3±0.2           -2.00±0.2              40.3±2.3             8.4                 7.6±0.24a1              -2.8±0.8 
Results are expressed as mean ±SEM, n=5, a = compared to Neg.control (7% Tween-80 
suspension, b=200mg/kg, 400mg/kg1= p < 0.05, 2= p < 0.01, 3= p < 0.001 ∞ = all treatments 
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Table 8.Body weight, temperature and PCV measurements in 4 days suppressive test of 
chloroform fraction of C.simensis roots 
Treatment 
groups(mg/kg) 
 
Wt.before      
 
Wt.after           
 
Temp.before      
 
Temp.after             
 
PCV.before            
 
PCV.after 
Pos.control          27.1±0.5           28.2±0.4         37.2±0.3         37±0.3                 52±0.9                52.6±0.9 
Neg.control          27.3±0.4          23.3±0.8         37.7±0.3         34.8±0.1              55±0.3                  46±2 
100 27.5±0.2          24±0.3            37.3±0.3         34.8±0.3             70.6±2.2                63±3.3 
200 26.6±0.8          24.7±1.4        36.7±0.2         35.5±0.4               70.0±1.4                  63.2±3 
400 27.6±0.3          26.4±1.2        36.9±0.1         35.7±0.1              73.2±2.1               67.4±2.9 
 
Table 9.Body weight, temperature, parasitemia, survival time and PCV measurements in 4 days 
suppressive test of chloroform fraction of C.simensis roots 
Treatment 
groups(mg/kg) 
Wt.diff.(g)    Temp.diff.(⁰C)        %Parasitemia    %Suppr
ession 
Survival(day)   %PCV.diff 
Pos.control       1.1±0.09a1        -0.14±0.098a3b2        0.00±0.00∞3                           30±0.00∞3        0.6±0.24a2 
Neg.control      -4.0±0.5              -2.94±0.35             72.6±1.36                    0               5.0±0.32           -9.0±1.8 
100 -3.43±0.26           -2.5±0.5                71.0±4.04             2.2              6.2±0.49          -7.6±1.3 
200 -1.9±2.15             -1.28±0.5a1             59±5.41              18.73           6.8±0.58           -6.8±1.9 
400 -1.22±1.33          -1.2±0.18a1             53.4±3.6a2
b
1         26.45         7.2±0.86
a
3
b
1      -5.8 ±1.16 
Results are expressed as mean ±SEM, n=5, a = compared to Neg.control (7% Tween-80 
suspension) b=comp.to100mg/kg, c=comp.to 200m/kg, d=comp.to400mg/kg, 1= p < 0.05, 2 = p 
< 0.01, 3= p < 0.001, ∞ = all treatments 
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Table 10.Tempreature, parasitemia and survival time measurements for Rane's test of 
chloroform fraction of C.simensis roots 
Treatment 
group(mg/kg) 
 
Temp.befor
e       
 
Temp.after      
 
Para-day 6          
 
Para-day 7          
 
Para. day 8          
% 
Inhi
bn 
 
Survival (day) 
Pos.control           37.2±0.3          37.1±0.3          3±0.16∞3        1.02±0.27∞3         0.00±0.00
∞
3                          30±0.000
∞
3 
Neg.control          37.7±0.3          34.8±0.1         21±1.14           22.8±0.97         23.4±0.75               0 5.6±0.24 
200 37.3±0.3          34.8±0.3         19.8±0.97        22 ±1.05          23.0±1.05            1.71              6.6±0.24 
400 36.7±0.2          35.5±0.4         17.6±1.89        18.4 ±1.4a1       19.0±1.18
 a
1
b
1      18.8           8.4±0.4a3
b
2 
600 36.9±0.1          35.7±0.1      13.8±0.73a2b1     10.2±0.66a3
b
3
c
3     9.4±0.68
a
3
b
3
c
3      59.8     10.8±0.37
a
3
b
3
c
3 
 
Results are expressed as mean ±SEM, n=5, a = compared to Neg.control (7% Tween-80 
suspension), b=comp.to 200mg/kg, c=comp.to 400mg/ kg   d=comp.to 600mg/kg, 1= p < 0.05, 2 
= p < 0.01, 3= p < 0.001, ∞ = all treatments, Para =parasitemia 
Table 11.Rectal temperature, weight and PCV measurements in Rane's test of chloroform 
fraction of C.simensis roots 
Treatment 
grps.(mg/kg) 
 
Wt.befor      
 
Wt.after          
 
PCV-befor           
 
PCVafter             
 
Wt.diff.             
 
Temp.diff                  
 
PCV.diff 
Pos.control 27.1±0.5          27.4±0.5        52±0.9               52.6±0.9              0.5±0.07∞3            0.06±0.07∞3     -1.52±0.22a3
b
2                        
Neg.control 27.3±0.4        24.1±0.1         55±0.3             50.4±0.7           -4.1±0.23             -8.13±0.49                   -15.5±2.5                           
200 27.5±0.2        24±0.3          70.6±2.2          58.6±6.5          -3.39±0.44            -7.4±0.53          -10.3±2.2                           
400 26.6±0.8         24.7±1.4         70±1.4               61.6±6.2           -2.58±0.17a2          -6.7 ±0.32a2      -7.3±0.54a2                           
600 27.6±0.3         26.4±1.2        73.2±2.1              67.4±2.9           -1.9 ±0.25a3
b
2        -4.98±0.32a3b2      -5.1±0.32a2                          
Results are expressed as mean ±SEM, n=5, a = compared to Negative control (7% Tween-80 
suspension) b=comp.to 200mg/kg, c=comp.to 400mg/kg, d=comp.to 600mg/kg, 1= p < 0.05, 2 = 
p < 0.01, 3= p < 0.001, ∞ = all treatments, Positive control=Chloroquine -25mg/kg. 
    
31 
 
5. Discussion 
No single solvent has the ability to extract and dissolve all the plant metabolites at once, rather 
several solvents of increasing polarity need to be used successively, such as hexane → ethyl-
acetate →chloroform → methanol → ethanol → water (39).Therefore, for our extraction we 
used methanol (for crude), n-hexane, chloroform and distilled water in order not to miss the polar 
and non-polar plant metabolites within the roots. 
Even though Ethiopian traditional medicine practitioners applied squeezing and homogenization 
techniques for the extraction of bioactive components from C. simensis roots for the treatment of 
malaria, for our study we used 80% aqueous methanol using maceration technique as it is the 
most effective solvent extracting both more polar and moderately polar plant constituents most 
efficiently from plant parts - alkaloids, flavonoids, phenolics etc (86-88). 
The yield of 80% methanolic crude extract was deep yellow semisolid mass, 166g (8.74%), from 
which we used 151g for fractionation: aqueous fraction 148.53g (98.37%), chloroform fraction 
2.13g (1.4%) and n-hexane 0.35g (0.23%). The least yield being the n-hexane fraction in 
consistent with a research on the leaves of Flueggea virosa-2.6% (89).And the activity resides on 
polar components. The probable reason for this great yield variation might be due to high 
concentration of polar compounds in the root of the plant species that better dissolve in water. 
But from a research report on the leaf of the same plant the yield was deep green semisolid and 
their percentages were; petroleum ether-13.5%, chloroform-5%, acetone-8.3%, methano-11.7%, 
the highest yield being in the non polar component in disagreement with our findings, however 
,the anti-inflammatory and anti-nociceptive activities still reside on the polar part(in acetone and 
methanol) (90).    
Changes in general behaviours, variations in body weight and morbidity are critical for the 
evaluation of the effect of a compound on test animals, since such changes are often the first 
signs of toxicity (76).Therefore this crude extract was tested for its toxicity against female Swiss 
albino mice. None of the test mice died or showed no signs of acute toxicity within 24 hours of 
treatment and then 14 days of follow up, up to 2g/kg, however, it doesn’t mean that it is safe in 
long term use. As a result its LD50 was assumed to be more than 2g/kg body weight. 
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Although chloroquine is not a first-line drug in the treatment of malaria in humans, it is used as 
control drug in this study as the P.berghei used for inoculation in this study is a chloroquine-
sensitive strain (77).When a standard antimalarial drug, 25mg/kg Chloroquine was used for 
treatment of mice infected with P. berghei (76), it clears parasitemia to undetectable levels, 0% 
in both crude and solvent fractions. 
Due to reasonably high homology and similarity between mammalian genetics and physiology 
and to the relatively short reproductive cycle, mouse  models are the most used for assessment of 
antiplasmodial activities of plant extracts and products derived from them and hence for our 
study we used female Swiss albino mice of age 8-9 weeks (39). In this age range, many 
developmental processes are going on and changes in physiology with age will have a large 
impact on experimental variables. For instance, B-cells have an immature phenotype until four 
weeks of age, T-cell responses mature around eight weeks of age, and T and B-lymphocyte 
production increases over the first 26 weeks of life. Development of mouse spinal cord, 
hippocampus and olfactory structures is ongoing until 11 weeks of age. In addition older animals 
entering senescence may respond differently to their younger counterparts (91). 
In vivo evaluation of antimalarial effects of our extract was done with the use of rodent malaria 
parasite, P. berghei as Plasmodium species that cause human disease are essentially unable to 
infect non-primate animal models (with the exception of a complex immunocompromised mouse 
model that has been developed to sustain P. falciparum-parasitized human erythrocytes in vivo) 
and rodent models have been validated through the identification of several antimalarials - for 
instance, mefloquine, halofantrine and artemisinin derivatives(77) and also it is cost effective 
preliminary pharmacological activity screening. 
In this study a four-day suppressive test - to evaluate antimalarial activities of extract on early 
infection and curative tests-to  evaluate curative potential on established infections were used  by 
comparison of blood parasitemia, PCV, weight change, temperature reduction and survival time 
in treated and untreated mice. 
Anemia, rectal temperature reduction, and reduction in body weight are the general features of 
malarial infection in mice and human malarial infections (92, 93). Therefore a potent 
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antimalarial is expected to improve anemia, prevent body weight loss, and stabilize temperature 
in infected mice with increasing parasitemia. 
From a research, anti-malarial activities of Maslinic acid (MA), a natural triterpene, which 
showed a parasitostatic action in-vitro on P. falciparum, analysed in vivo on international center 
for research-ICR mice using the P. yoelii 17XL murine model (Py17XL), the survival increased 
from 20 to 80% after four-day suppressive MA test with a dose of 40 mg Kg/day on Py17XL 
infected mice with a parasitemia profile similar to that of the untreated mice. That  was due to 
the parasitostatic effect exerted by MA during the first days of infection (94).  
The same analogy might be applied here, our crude extract’s parasitemia reduction in a four-day 
suppressive test was not statistically significant but % suppression was 21.5% (i.e. mean 
parasitemia level=78.5%) for 400mg/kg compared with negative control and  mean group 
parasitemia level of ≤ 90% of that of treated versus negative control animals usually indicates 
that the test compound is active in standard screening studies(95, 96), in addition, this dose 
brought significant survival benefit in comparison with 100mg/kg (P ˂0.05) and negative control 
(P˂0.05) this might be attributed from parasitostatic effect of our extract having terpenoid 
component or so in consistent with the above report , and that might favour the development of 
more effective sterilizing immune responses. In the same manner 400mg/kg aqueous fraction 
showed survival advantage in a four-day suppressive test in comparison with 100mg/kg (P˂0.01) 
and negative control (P˂0.01)but this dose brought no statistically significant parasitemia 
reduction(% suppression=22.5), this might be due to the fact that the aqueous fraction has 
parasitostatic effect.  
Additionally our crude extract’s % suppression was 53.54 (i.e. mean parasitemia level = 46.46%) 
and parasitemia reduction was statistically significant for 600mg/kg compared with negative 
control, 100mg/kg and 200mg/kg (P<0.001), with 400mg/kg (P<0.05) and. This same dose gave 
significant survival advantage in relation with negative control and 100mg/kg (P< 0.001), with 
200mg/kg (P<0.01).(Table3) Due to these findings and the above reports we passed on to 
fractions screening as the  “Thompson Survival Assay” and the  “Peters’ 4-day tests” are the 
most widely used efficacy assays in malaria (77, 97) 
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PCV was measured in this study to determine the effectiveness of both crude extract and solvent 
fractions (i.e., aqueous, chloroform and hexane fractions) of C.simensis root in preventing 
malaria-induced hemolysis. Saponins having amphiphilic properties can interfere with biological 
surfaces such as cell membranes-including erythrocyte membranes. This may result in 
haemolysis as a consequence of perturbation and loss of the cell membrane integrity (which are 
non-specific and may affect wide range of organisms (98)) but with unknown mechanism (93).In 
addition, saponins reduce protein digestibility by formation of saponin-protein complexes and 
obstruct the absorption of micronutrients (98). In our extract no saponins were found, therefore 
that insignificant hemolysis observed in all treated and control groups in Peters’ 4-day tests were 
due to the parasitemia level only. 
There was reduction of rectal temperature with increasing parasitemia in the infected mice, in all 
the crude and fractions’ doses administered but the positive control didn’t. The reduced rectal 
temperature might be attributed to reduced metabolic activities due to the progressive infection 
and accompanying appetite.   
From amongst the treatment groups the highest dose 600 and 400mg/kg crude extract showed 
comparable significant temperature stabilizing effect (P˂0.05) and 400mg/kg chloroform fraction 
also significantly controlled the temperature reduction (P˂0.05) followed by 200mg/kg of the 
same fraction (P˂0.05) in relation to the negative control but all other treatments did not stabilize 
temperature in Peter’s test. (Table3)  
The 400mg/kg chloroform fraction also showed significant parasitemia reduction (p<0.01), 
(p<0.05) and survival benefit (p<0.001),(p<0.05)when compaired with negative control and 
100mg/kg, respectively. The fact that 400mg/kg chloroform fraction showed the highest 
reduction of parasites but all other treatment groups ( crude and fractions) showed no significant 
parasitemia reduction by this dose; suggests that the active ingredients of this plant responsible 
for its antimalarial activities may be localized in this fraction, like the research conducted on C. 
macrostachyus (78). In addition % suppression of this dose was 26.45% in 4-days Peter’s test 
when compared with negative control (Table9).  
Insignificant weight loss was recorded in all the doses of crude extract and solvent fractions of C. 
simensis administered, but there was significant weight reduction in negative control in relation 
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to positive one. This result shows that, the extract has controlled the weight lose that would 
otherwise be expected in malaria infection. This  change might be solely due to reduced feed 
intake by the influence of the parasite itself as the extracts are negative for appetite suppressing 
components like saponins, glycosides and tannins (92, 99). This suppression might be due to the 
precipitation of proteins and gastrointestinal enzymes thereby reducing the digestibility and 
availability of proteins (98). The n-hexane fraction brought no significant advantage, except 
survival benefit when we evaluated it by using the five parameters mentioned above. 
In this study we have also conducted Rane’s test; after the last day of treatment parasitemia and 
survival advantage were found to be significant for 400mg/kg (P<0.05) and (P<0.001, P<0.01) 
compared with negative control and 200mg/kg respectively, for 600mg/kg compared with 
negative control, 200mg/kg and 400mg/kg (P<0.001) dose dependently. In addition survival time 
to more than twice that of the negative controls is considered as evidence of activity (31). 
Correspondingly, significant control of weight and temperature reduction were observed in 
relation with negative control, for 400mg/kg (P<0.01), for 600mg/kg (P<0.001), additionally for 
600mg/kg in relation with 200mg/kg (P<0.01). PCV was significant too for 600 and 400mg/kg 
(P<0.01) in comparison with negative control (Table11). 
The chemotaxonomy of the genes Clematis is carried out using flavonoids, triterpenoid saponins, 
ribose, etc profiles as chemical markers for the taxonomy of the Ranunculaceae (47, 49). Our 
study showed that C. simensis root has the following secondary metabolites which have been 
suggested to be responsible for antiplasmodial activity of other plants; alkaloids, flavonoids, 
terpenoids and phenols in agreement with the above report but saponins. Therefore, the observed 
antimalarial activity could be associated with some of the alkaloids and other constituents 
reported from the plant in synergy (100) , as alkaloids such as quinine (98), sesquiterpene  
trioxane lactone (Artemisinin) (101) and flavonoids (100) are known for their antimalarial 
activities. Also chemo-taxonomical survey revealed that alkaloids are widely distributed in 
higher plants like Ranunculaceae (98), this is in agreement with our finding in that we observed  
alkaloid in both Wagner’s and Mayer’s tests during phytochemical screening. 
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Oxidative stress is observed in the malaria development. Plasmodia digest haemoglobin which 
results in the production of heme and heme triggers the production of reactive oxygen SPP. 
which are implicated in the pathophysiology of malaria and can lead to anemia and apoptosis. 
Plants having a high concentration of phenolic compounds like phenol itself and flavonoids 
(poly-phenols) are a reservoir of novel antioxidant molecules (102). A study showed the 
hepatoprotective (antioxidant) effect of C. chinensis extract on CCL4-induced hepatotoxicity in 
rats and the results of aminetransferase, aspartate aminetransferase and alanine aminetransferase 
, oxidant defence  enzymes , have shown a significant hepatoprotective effect after treatment 
with C. Chinensis (52). In our study we have found phenolic metabolites too, and the observed 
antimalarial effect may come from these and other metabolites screened.  
Ethno pharmacologically different parts of C. Simensis  are reported to be a remedy for 
analgesia, and malaria (68, 70) , malaria  and liver disease (71) and anti-inflammatory and 
antibacterial in humans (54) as inflammation is one of the complications of malaria parasite 
infection and drugs having antibacterial activity such as tetracycline and its derivatives have 
been used in malarial treatment. Various Clematis species have been shown experimentally to 
exhibit significant anti inflammatory and analgesic activities (47, 49). Methanolic extract of 
C.campestris; flower, showed good in vitro antiplasmodial activity against P. falciparum (59). 
Our evaluation of the plant against a strain of P.berghei in vivo proved significant antimalarial 
activities with no toxicity up to 2g/kg, in agreement with another study on in vivo anti 
inflammatory and anti-nociceptive activities of the leaf extracts of the same plant having no 
toxicity from 2-5mg/kg(90) .  
The results of this study were therefore, in consistent with the traditional use of this plant for 
antimalarial therapy. Therefore, this study together with the aforementioned reports showed that 
the plant may serve as a potential source of different antiplasmodial compounds. 
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6. Limitation of the Study 
We haven’t done sub acute toxicity and quantitative phytochemical tests and these limit the 
importance of this study. 
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7. Conclusion 
The hydroalcholic crude extract and chloroform fraction showed significant antimalarial 
activities and the present study has demonstrated that the antimalarial activity of the plant was 
significantly improved through fractionation of the methanolic crude extract of its roots. These 
results suggest that the Kunama and Gumuz ethnic groups of Ethiopia antimalarial application of 
C. simensis have a pharmacological basis. These results suggest that it is possible to isolate 
active anti-malarial compounds from the extract as well as to determine their mechanism(s) of 
action. 
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8. Recommendation 
From our study, the following works are suggested for further investigation on the plant; further 
phytochemical investigation to clearly identify and quantify the antiplasmodial active 
components from the plant, sub acute and chronic toxicity study to know the safety of C. 
simensis roots and investigation of in-vivo antimalarial activities against non P.berghei spp. in 
order to consider them as potential sources for antimalarial drug development for human malaria.  
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Annex 
 Test for phenols 
The plant’s solvent extract was put in a test tube and treated with 3-4 drops of 2% of FeCl3. 
Formation of bluish black/ bluish green coloration indicated the presence of phenols(103, 104).      
Test for saponins  
Foam Test - 0.5 gm of extract was shaken with 2 ml of water. If foam produced persists for ten 
minutes it indicates the presence of saponins(103).     
Test for alkaloids 
1-Wagner’s Test: Filtrates were treated with Wagner’s reagent (Iodine in Potassium Iodide). 
Formation of brown/reddish precipitate indicates the presence of alkaloids(103). 
2- Mayer’s Test: a few ml of extract was mixed with 2 drops of Mayer’s reagent by adding at 
the side of the test tube, white creamy precipitate indicates the presence of alkaloids. 
Test for Flavonoids (Alkaline reagent test) 
2ml of extracts was treated with few drops of 20% sodium hydroxide solution. Formation of 
intense yellow colour, which becomes colourless on addition of dilute hydrochloric acid, 
indicates the presence of flavonoids (105).  
    
52 
 
Test of anthraquinones 
50mg of the test compound was diluted in 2 ml of chloroform, homogenized and filtered. Next, 1 
ml of 10% NaOH was added to 1 ml of the filtrate. The presence of anthraquinones was 
indicated by the appearance of a red coloration (106).            
 
 
 
Test for Tannins (Braymer’s test) 
2mls of extract was treated with 10% alcoholic ferric chloride solution and observed for 
formation of blue or greenish color indicates presence of tannins(105).   
Test for terpenoids (Salkowski test): 
 Five ml of the extract was mixed in 2 ml of chloroform, and 3ml concentrated H2S04 was 
carefully added to form a layer. A reddish brown colouration of the inter face was formed to 
show positive results for the presence of terpenoid (107). 
Test for cardiac glycosides (Keller-Killani test): Five ml of each extracts was treated with 2 ml 
of glacial acetic acid containing one drop of ferric chloride solution. This was underlayed with 1 
ml of concentrated sulphuric acid. A brown ring of the interface indicates a deoxysugar 
characteristic of cardenolides. A violet ring may appear below the brown ring, while in the acetic 
acid layer, a greenish ring may form just gradually throughout thin layer (107).                 
Test for Steroids-1mL of extracts was dissolved in 10 ml of chloroform and equal volume of 
concentrated H2SO4 was added by sides of the test tube. The upper layer showed yellow with 
green fluorescence. This indicates the presence of steroids (108).               
 
